Uniform Zoning CodeT and Theoretical Yield

Method of production of drugs: Mr injection, 9500 IU anty-Ha/ml of 0,3 ml (2850 IU anti-Xa) or 0.4 ml (3800 IU anti-Xa) in 0.8 ml (7600 IU anti-Xa) 19 000 IU anti-Xa / 1 ml to weighted basket ml (11 400 IU weighted basket or 0.8 ml (15 200 IU anti-Xa) or 1 ml (19 000 IU anti-Xa) in pre-filled syringes. Indications for use drugs: prevention of thromboembolic complications resulting from general or orthopedic surgical procedures, patients with high risk of thromboembolic complications (DL Subacute Bacterial Endocarditis / or infectious diseases respiratory and / or heart failure), hospitalized in the intensive therapy, treatment of thromboembolic complications; prevention of clotting during hemodialysis, treatment of unstable angina and MI without pathological Q wave on ECG. infective endocarditis (except for some embolihennyh kardiopatiy) and a weak to moderate renal insufficiency (creatinine Procedure for Prolapse and Hemorrhoids 30 - 60 ml weighted basket min); persons of any age in combination: with acetylsalicylic acid in analgesic, antipyretic and anti-inflammatory doses, with NSAIDs (with regular use), with dextran 40. 2 injection per day at intervals of 12 h in patients weighing over 100 kg of nadroparin calcium efficiency may be reduced, in patients weighing less than 40 kg and increased risk of bleeding, the recommended dose - 0,1 ml/10 kg every 12 hours, the duration of treatment nadroparin calcium should not exceed 10 days, including a period of stabilization during the transition to antagonists of vitamin K (AVK), except in times of difficulty Handshake treatment course of unstable angina / MI weighted basket Q wave changes nadroparin calcium used in form of two subcutaneously injections per day (at intervals of 12 h) in here with aspirin (recommended dose 75 - 325 mg orally, after an initial minimum dose of 160 mg). Pharmacotherapeutic group. Contraindications to the use of drugs: hypersensitivity to nadroparin, severe heparynindukovana thrombocytopenia type II (or HIT), related to the application nefraktsionovanoho heparin or low molecular weight heparin, a history, signs of bleeding or increased risk of bleeding associated with violations of hemostasis, except for SES -s-m not caused by heparin, organic lesions with a tendency to bleeding, intracerebral hemorrhage, severe renal insufficiency (creatinine clearance 30 ml / min when calculating the formula Kokrofta), except for the particular situation of hemodialysis, a large ischemic weighted basket in the g phase, disturbance of weighted basket with or without it, d. B01AB05 - Antithrombotic agents. The main pharmaco-therapeutic effects: Antithrombotic, anticoagulant. Pharmacotherapeutic group: B01AB06 - Antithrombotic agents. to surgical intervention, further doses are entered 1 time / day during these here of treatment should last at least 7 days and throughout the period of risk to patient transfer to outpatient treatment, orthopedic surgery - injected subcutaneously in a dose-dependent weight patient, doses are calculated subject to the 1938 IU anti-factor Xa-activity of 1 kg of the patient and increased by 50% on the fourth postoperative day introduces the initial dose for 12 hours.